AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations

Breast cancer was one of the first malignancies to benefit from targeted therapy, i.e., treatments directed against specific markers. Inhibitors against HER2 are a significant example and they improved the life expectancy of a large cohort of patients. Research on new biomarkers, therefore, is alway...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Int J Mol Sci
Auteurs principaux: Falcone, Italia, Conciatori, Fabiana, Bazzichetto, Chiara, Bria, Emilio, Carbognin, Luisa, Malaguti, Paola, Ferretti, Gianluigi, Cognetti, Francesco, Milella, Michele, Ciuffreda, Ludovica
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7696061/
https://ncbi.nlm.nih.gov/pubmed/33182542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21228419
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires